Lineage B.1.1.7

Sixth Wave Detects UK and South African Variants of SARS-CoV-2

Thursday, June 10, 2021 - 12:00pm

The virus variants detected include the UK variant and the South African variant.

Key Points: 
  • The virus variants detected include the UK variant and the South African variant.
  • There are documented cases of new variants circumventing the human immune system and causing reinfection and drastically reduced efficacy of certain vaccines.
  • Sixth Wave continues to expand the capabilities of the AMIP diagnostic platform as it works on improving the specificity and sensitivity in their prototype devices.
  • Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries.

Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Tuesday, June 1, 2021 - 10:03am

Starpharma is alsotesting the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks.

Key Points: 
  • Starpharma is alsotesting the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks.
  • The antiviral testing was conducted by the renowned Scripps Research Institute in the US, with the UK variant of SARS-CoV-2, which has been classified as a variant of concern.
  • The UK variant was recently reported to be responsible for over 98% of the positive COVID infections in England and linked to multiple outbreaks worldwide.
  • Viraleze is registered for sale in Europe and the UK, and is available through one of the UK's largest pharmacy chains, LloydsPharmacy.

Global is Going Mobile; Global WholeHealth Partners Corp (GWHP-OTC) has Signed an Agreement With Dr. Vu Le to be the Medical Director for the CLIA WAIVED Mobile Laboratory

Thursday, May 20, 2021 - 12:00pm

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein.
  • Investors and security holders are urged to read these documents free of charge on the SEC\'s web site at http://www.sec.gov .
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

ECDC releases new dashboard on SARS-CoV-2 variants

Thursday, May 20, 2021 - 8:00am

Data for the most recent reporting week have been excluded, as they may be incomplete.

Key Points: 
  • Data for the most recent reporting week have been excluded, as they may be incomplete.
  • The proportion of variants is only reliable when sequencing capacity is adequate (500 or 10% of total samples).
  • For TESSy data, no proportion of variants has been estimated where there is no reliable denominator available.
  • In addition, SARS-CoV-2 lineages B.1.617.1, B.1.617.2, and B.1.617.3, first reported in India in December 2020, have been increasingly detected in other countries.

Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)

Tuesday, May 18, 2021 - 7:39am

CT-P59 is known to successfully neutralise the SARS-CoV-2 variants first identified in the UK (B.1.1.7), California (B.1.427/B.1.429), Brazil (P.2), in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S\xc2\xb7L\xc2\xb7V\xc2\xb7G\xc2\xb7GH\xc2\xb7GR).\n\xe2\x80\x9cThe emergence of SARS-CoV-2 variants has created great concern across the globe.

Key Points: 
  • CT-P59 is known to successfully neutralise the SARS-CoV-2 variants first identified in the UK (B.1.1.7), California (B.1.427/B.1.429), Brazil (P.2), in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S\xc2\xb7L\xc2\xb7V\xc2\xb7G\xc2\xb7GH\xc2\xb7GR).\n\xe2\x80\x9cThe emergence of SARS-CoV-2 variants has created great concern across the globe.
  • \xe2\x80\x9cMonoclonal antibodies have the potential to alleviate symptoms and prevent progression to severe disease in patients with mild to moderate COVID-19.
  • Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries.
  • For more information please visit: https://www.celltrionhealthcare.com/en-us .\nCT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus.

Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern

Tuesday, May 18, 2021 - 4:39am

B.1.351 S-Trimer demonstrated broad neutralization against the original SARS-CoV-2 strain and variants of concern, specifically the South African variant (B.1.351), Brazil variant (P.1), and UK variant (B.1.1.7).

Key Points: 
  • B.1.351 S-Trimer demonstrated broad neutralization against the original SARS-CoV-2 strain and variants of concern, specifically the South African variant (B.1.351), Brazil variant (P.1), and UK variant (B.1.1.7).
  • Clover is at the forefront of vaccine R&D utilizing our proprietary Trimer-Tag technology and is the first company to disclose preclinical data demonstrating that a modified protein-based COVID-19 vaccine candidate can potentially induce broad neutralization against the original SARS-CoV-2 strain and variants of concern," said Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals.
  • As the SARS-CoV-2 virus mutates and additional data emerges, we are prepared to innovate and develop next-generation COVID-19 vaccines.
  • Any forward-looking statement made by us in this document speaks only as of the date on which it is made.

Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant

Monday, May 17, 2021 - 8:00am

b'Memo Therapeutics AG (\xe2\x80\x9cMemo\xe2\x80\x9d), an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).

Key Points: 
  • b'Memo Therapeutics AG (\xe2\x80\x9cMemo\xe2\x80\x9d), an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).
  • Memo is now preparing MTX-COVAB for clinical evaluation.\nUsing its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo can discover novel antibodies at unprecedented speed, efficiency and sensitivity derived from recovered patient samples.
  • This can be achieved in as little as 3 weeks from receiving the blood sample.\n\xe2\x80\x9cAddressing SARS-CoV-2 variants remains a global challenge and one that will remain.
  • Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005220/en/\n'

Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2  

Monday, May 3, 2021 - 12:30pm

As previously disclosed, a study conducted by ICMR also suggested that COVAXIN was effective against the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617.

Key Points: 
  • As previously disclosed, a study conducted by ICMR also suggested that COVAXIN was effective against the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617.
  • We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.
  • This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

SARS-CoV-2 variants of concern pose a higher risk for hospitalisation and intensive care admission

Saturday, May 1, 2021 - 12:04am

A study coordinated by ECDC together with seven EU countries Cyprus, Estonia, Finland, Ireland, Italy, Luxembourg, and Portugal analysed data on the three VOC reported by the collaborating countries, and the research shows a higher risk for hospitalisation and intensive care admission.

Key Points: 
  • A study coordinated by ECDC together with seven EU countries Cyprus, Estonia, Finland, Ireland, Italy, Luxembourg, and Portugal analysed data on the three VOC reported by the collaborating countries, and the research shows a higher risk for hospitalisation and intensive care admission.
  • The analysis of 19 995 VOC and 3 348 non-VOC cases suggests that the VOC pose a higher risk for developing severe diseases.
  • Compared to cases infected with a non-VOC virus, the risk for hospitalisation in B.1.1.7 cases was 1.7 times higher, while in B.1.351 it was 3.6 times higher and for P.1 it was 2.6 times higher.
  • This study also showed an increased risk of being admitted to intensive care by 2.3, 3.3 and 2.2 times higher for people infected by B.1.1.7, B.1.351 and P.1 respectively, compared to non-VOC cases.

Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic

Monday, April 12, 2021 - 1:04pm

The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.

Key Points: 
  • The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.
  • "Seegene will continue to closely monitor developments on the virus variant front and provide additional variant tests to help contain the spread of the virus and put an end to the pandemic.
  • the so-called "UK variant" has proven to be not only more contagious but also deadlier, raising alarm across the world.
  • Seegene continues to set new standards in MDx providing new, cost-effective innovations.\n'